Expressed with the mutations of K417N, L452R, T478K.
|Biological Activity||This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay.|
The optimal dilution ratio should be determined by the end user for specific applications.
|Formulation||Supplied as a solution in PBS, pH 7.4, 0.1% ProClin 300.|
|Storage & Stability||Upon receiving, this product remains stable for up to 3 months at 2-8°C. Protect from light.|
|Target Background||SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. The Delta Plus variant, also known as B.1.617.2.1 or AY.1, is considered a “subvariant” of the Delta version, which has a mutation (K417N) that allows the virus to better attack lung cells and potentially escape vaccines.|
|Synonyms||B.1.617.2.1; Delta Plus variant; AY.1|
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
For more documents, please visit "Technical Support".